Recent advances in biosensors for neurodegenerative disease detection

Abstract Neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD), Parkinson's disease (PD) and Prion diseases are known as ‘protein misfolding disorders’ because aggregation prone proteins are postulated to be the underlying causative agents in these diseases. The economic impact of NDDs, including human and non-human costs, are quite staggering and represents a significant public health challenge for nations around the world. Technology development that facilitates early detection of NDDs, is therefore, the need of the hour. Various analytical technologies have been developed to address this challenge, in the hope of evolving effective therapeutic strategies against NDDs. Over the past decade, biosensors based on optical and electrochemical techniques have been at the forefront of this development, thanks to advances in material science such as carbon nanotubes (CNTs), gold nanoparticles (AuNPs), and quantum dots (QDs). In this review, we evaluate the most recent advances in optical and electrochemical biosensors for detection of NDDs.

[1]  Geng-fu Xiao,et al.  Gold nanoparticles as a label-free probe for the detection of amyloidogenic protein. , 2012, Talanta.

[2]  Vladimir N Uversky,et al.  A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.

[3]  Mun'delanji C. Vestergaard,et al.  Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip. , 2008, Talanta.

[4]  Gulsah Congur,et al.  Label-free voltammetric detection of MicroRNAs at multi-channel screen printed array of electrodes comparison to graphite sensors. , 2014, Talanta.

[5]  Philip L De Jager,et al.  Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.

[6]  R. Kayed,et al.  Preparation and characterization of neurotoxic tau oligomers. , 2010, Biochemistry.

[7]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[8]  S. R. Ankireddy,et al.  Selective detection of dopamine in the presence of ascorbic acid via fluorescence quenching of InP/ZnS quantum dots , 2015, International journal of nanomedicine.

[9]  M. Bennett.  The role of α-synuclein in neurodegenerative diseases , 2005 .

[10]  Arben Merkoçi,et al.  Signal enhancement in antibody microarrays using quantum dots nanocrystals: application to potential Alzheimer's disease biomarker screening. , 2012, Analytical chemistry.

[11]  E. Dufour-Gergam,et al.  A new controlled concept of immune-sensing platform for specific detection of Alzheimer's biomarkers. , 2013, Biosensors & bioelectronics.

[12]  S. Paul,et al.  Protein‐misfolding diseases and chaperone‐based therapeutic approaches , 2006, The FEBS journal.

[13]  G Marrazza,et al.  Detection of human apolipoprotein E genotypes by DNA electrochemical biosensor coupled with PCR. , 2000, Clinical chemistry.

[14]  Y. Sohn,et al.  Detection of Amyloid-β42 Using a Waveguide-Coupled Bimetallic Surface Plasmon Resonance Sensor Chip in the Intensity Measurement Mode , 2014, PloS one.

[15]  K. Weisgraber,et al.  Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy. , 2009, Journal of molecular biology.

[16]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[17]  Abbas Ali Mahdi,et al.  Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.

[18]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Sola,et al.  Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. , 2013, Biosensors & bioelectronics.

[20]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  T. Shibata,et al.  Sensitive Chemiluminescence Detection of Prion Protein on a Membrane by Using a Peroxidase-Labeled Dextran Probe , 2011, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[22]  K. Yanagisawa,et al.  Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients , 2000, European Neurology.

[23]  Sara Tombelli,et al.  A new approach for the detection of DNA sequences in amplified nucleic acids by a surface plasmon resonance biosensor. , 2004, Biosensors & bioelectronics.

[24]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[25]  B. Mollenhauer,et al.  Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. , 2012, Methods.

[26]  E. Dufour-Gergam,et al.  Chemical engineering of self-assembled Alzheimer's peptide on a silanized silicon surface. , 2014, Langmuir : the ACS journal of surfaces and colloids.

[27]  Zhen Gu,et al.  Ubiquinone-quantum dot bioconjugates for in vitro and intracellular complex I sensing , 2013, Scientific Reports.

[28]  T. Osaka,et al.  Sensitive electrical detection of human prion proteins using field effect transistor biosensor with dual-ligand binding amplification. , 2015, Biosensors & bioelectronics.

[29]  Zhiyuan Hu,et al.  Label-free detection of Alzheimer's disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. , 2015, Chemical communications.

[30]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[31]  S. Prasad,et al.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[32]  W. Klein,et al.  The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. , 2009, The American journal of pathology.

[33]  B. Hyman,et al.  Soluble forms of tau are toxic in Alzheimer’s disease , 2012, Translational neuroscience.

[34]  Hanna Trzeciakiewicz,et al.  A protein-based electrochemical biosensor for detection of tau protein, a neurodegenerative disease biomarker. , 2014, The Analyst.

[35]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[36]  M. Prince,et al.  World Alzheimer Report 2013 , 2014 .

[37]  P. Calabresi,et al.  Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias , 2011, Movement disorders : official journal of the Movement Disorder Society.

[38]  Arben Merkoçi,et al.  Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. , 2015, Biosensors & bioelectronics.

[39]  Adem Yildirim,et al.  Turn-on fluorescent dopamine sensing based on in situ formation of visible light emitting polydopamine nanoparticles. , 2014, Analytical chemistry.

[40]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[41]  P. Jensen,et al.  Pathogenic effects of α-synuclein aggregation , 2005 .

[42]  D. Dickson.  Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[43]  M. Meraz-Ríos,et al.  Tau oligomers and aggregation in Alzheimer’s disease , 2010, Journal of neurochemistry.

[44]  Tatsuro Endo,et al.  Au nanoparticle-modified DNA sensor based on simultaneous electrochemical impedance spectroscopy and localized surface plasmon resonance. , 2014, Biosensors & bioelectronics.

[45]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Ning Xia,et al.  Regenerable and simultaneous surface plasmon resonance detection of aβ(1-40) and aβ(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. , 2010, Analytical chemistry.

[47]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[48]  Wang Haiying,et al.  A rapid method for detection of PrP by surface plasmon resonance (SPR) , 2009, Archives of Virology.

[49]  C. Wellington,et al.  Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease , 2007, Current opinion in lipidology.

[50]  Y. Ihara,et al.  The car☐yl third of tau is tightly bound to paired helical filaments , 1988, Neuron.

[51]  Alexandre François,et al.  Radiative-surface plasmon resonance for the detection of apolipoprotein E in medical diagnostics applications. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[52]  T. Hianik,et al.  Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. , 2014, Biosensors & bioelectronics.

[53]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[54]  B. Chesebro.  Introduction to the transmissible spongiform encephalopathies or prion diseases. , 2003, British medical bulletin.

[55]  M. Medina‐Sánchez,et al.  On-chip magneto-immunoassay for Alzheimer's biomarker electrochemical detection by using quantum dots as labels. , 2014, Biosensors & bioelectronics.

[56]  C. Davie.  A review of Parkinson's disease. , 2008, British medical bulletin.

[57]  Josephine A. Wright,et al.  Unique copper‐induced oligomers mediate alpha‐synuclein toxicity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[59]  J. Wesson Ashford,et al.  ApoE genotype accounts for the vast majority of AD risk and AD pathology , 2004, Neurobiology of Aging.

[60]  S Tombelli,et al.  Coupling of a DNA piezoelectric biosensor and polymerase chain reaction to detect apolipoprotein E polymorphisms. , 2000, Biosensors & bioelectronics.

[61]  Adriano Aguzzi,et al.  Pathogenesis of prion diseases: current status and future outlook , 2006, Nature Reviews Microbiology.

[62]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[63]  G. Evtugyn,et al.  EQCM biosensors based on DNA aptamers and antibodies for rapid detection of prions. , 2009, Protein and peptide letters.

[64]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[65]  G. Shi,et al.  A method for evaluating the level of soluble β-amyloid(1-40/1-42) in Alzheimer's disease based on the binding of gelsolin to β-amyloid peptides. , 2014, Angewandte Chemie.

[66]  K. Weisgraber,et al.  Apolipoprotein E structure: insights into function. , 2006, Trends in biochemical sciences.

[67]  Ning Xia,et al.  Electrochemical detection of β-amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O2 reduction by Aβ(1-16)-heme-modified gold nanoparticles. , 2013, Biosensors & bioelectronics.

[68]  Tae Hoon Lee,et al.  ZnO nanowire arrays on 3D hierachical graphene foam: biomarker detection of Parkinson's disease. , 2014, ACS nano.

[69]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[70]  Tibor Hianik,et al.  Electrochemical aptasensor of human cellular prion based on multiwalled carbon nanotubes modified with dendrimers: a platform for connecting redox markers and aptamers. , 2013, Analytical chemistry.

[71]  T. Shibata,et al.  Aptamer-mediated chemiluminescence detection of prion protein on a membrane using trimethoxyphenylglyoxal. , 2010, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[72]  U. Krull,et al.  Localized surface plasmon resonance: nanostructures, bioassays and biosensing--a review. , 2011, Analytica chimica acta.

[73]  Elizabeth L. Bennett,et al.  Wildlife Trade and Global Disease Emergence , 2005, Emerging infectious diseases.

[74]  V. Gupta,et al.  Lipid-induced Extension of Apolipoprotein E Helix 4 Correlates with Low Density Lipoprotein Receptor Binding Ability* , 2006, Journal of Biological Chemistry.